More encouraging are the recently developed anti-ERBB/ERBB2/ERBB3 targeted therapies for the treatment of carcinomas harboring NRG1 fusions, as would be considered for our patient if her tumor were to eventually recur. Here, ERBB3 is linked to carcinoma.